Abbreviations: DSA = donor-specific antibody; MCS = mean channel fluorescence; MFI = mean fluorescence intensity; ND = not determined.
Matching donor and recipient for HLA class I (-A, -B and -C) and class II (-DRB1 and -DQB1) haplotypes is a key part of successful allogeneic hematopoietic stem cell transplantation (AHSCT). Currently there are almost 14 500 HLA alleles, which is up from 12 000 alleles 2 years ago and despite the expansion of worldwide unrelated donor registries, the chances of finding a phenotypically matched unrelated donor vary, from 75% for Caucasians to under 20% for ethnic minorities. 1 This has led to the emergence of alternative options with less stringent requirements for HLA matching like umbilical cord HSCT (UCBT) and haploidentical HSCT. However, it is vital to screen for the presence of anti-HLA antibodies especially for antibodies directed against the donorsmismatched HLA antigen or donor-specific antibodies (DSAs). The role of DSAs in solid organ transplant rejection is well known. 2 In AHSCT, DSAs have been associated with primary graft failure after either an 8/8-matched-unrelated AHSCT or UCBT. In haploidentical transplants, 75% of patients with DSAs with median fluorescent intensity 41500 failed to engraft. 3 With the increasing use of haploidentical donors, the presence of preformed DSAs will play a vital role in graft survival.
DSAs were initially tested using a complement-dependent microlymphocytotoxicity assay 4 described in 1968, and was the standard internationally recognized method for detection of anti-HLA antibodies for 30 years. Subsequently solid-phase assays (SpA) were introduced wherein anti-HLA antibodies were identified by detecting their binding to HLA peptides immobilized on a solid surface. The current fluorescence-based SpA is able to concurrently distinguish up to 100 different microparticles or beads. Each bead contains a single HLA antigen and the beads contain a unique ratio of different fluorochromes that provide a distinctive signal that is recognized by Luminex technology. 5 The patient's serum is incubated with the beads and a fluorescent-conjugated anti-human IgG binds to alloantibody bound to its antigenic target. The output referred to as mean fluorescence intensity (MFI) is considered as a semi-quantitative measure of the amount of antibody present. These methods have increased the number of transplant candidates recognized to have lower levels of preexisting sensitization. Using these techniques, the rates of sensitization range from 20 to 40% of patients with any HLA antibodies and up to 24% of patients with DSA. 3, [6] [7] [8] [9] [10] [11] Limited donor options and /or an urgent need to proceed to transplant have led physicians to attempt various means to lower DSA to levels that would permit successful donor stem cell engraftment. 6, [11] [12] [13] [14] Current practice is to screen all recipients with HLA mismatch for DSAs and consider their significance if the titers are 41000 MFI. Even though SpA is the most sensitive method for detection of HLA antibody, it has limitations, which include antigen coverage, false-positive results due to phenomenon like antibody to denatured form of antigen and false-negative results due to prozone phenomenon. Here we present a case of unique DSA prototype detected by Luminex SpA to a haploidentical donor that was also shared with the recipient, in other words a self antibody which is a case of clinical conundrum.
A 55-year-old Caucasian woman was diagnosed with chronic myelomonocytic leukemia (CMML-2) in June 2015 when she presented with anemia. Over the next few months her symptoms gradually worsened with progressive dyspnea and fatigue. She had a repeat bone marrow biopsy in October 2015, which confirmed progression of CMML to acute myeloid leukemia with 50% blasts. Cytogenetics revealed trisomy 8 in 4 of the 20 metaphases (47 XX, +8 [4] /46, XX [16] ). She underwent induction chemotherapy with idarubicin and cytarabine (3+7), and her day 14 bone marrow although hypocellular showed no residual disease. She went on to receive one cycle of consolidation chemotherapy with high dose cytarabine (HiDAC) when she was worked up for HSCT. She had no matched sibling or unrelated donors based on the registry search. Available transplant options were her haploidentical daughter or double umbilical cord transplantation. Thus she was enrolled on the BMT Clinical Trials Network (CTN) 1101 trial, evaluating double-UCBT versus haploidentical-related HSCT for hematologic malignancies. She was randomized to the haploidentical donor arm. As part of the pre-transplant workup, the patient's serum was screened for HLA antibodies by the single antigen bead (SAB). Results revealed the presence of DSA: HLA-DRB1*04:04 (MFI = 2079) and HLA-A*24:02 (MFI = 859). Incidentally these were the alleles she shared with the donor or in other words, results demonstrated that these DSAs were also antibodies to self. Additional tests included repeat testing with another sample, which returned a similar DSA pattern thereby ruling out a sample mix up, testing using a different vendor product, which still demonstrated a similar DSA pattern and testing for the likelihood of the presence of antibody reacting to the denatured form of antigen on the bead as previously reported, 15 which was negative. As the recipient had received multiple blood products, it was thus presumed that this reactivity was likely due to a passive transfer of anti-HLA antibodies by blood transfusions. Such antibody levels will decrease over a period of time and thus we decided to serially monitor the patient's sera for the DSA levels ( Table 1) . DSA levels decreased for the first 2 months, however the sample from February 2016 demonstrated an increase in the MFI for antibodies to DRB1*04:04. This level of reactivity would potentially make the patient ineligible to participate in the clinical trial (CTN 1101).
To understand the clinical significance of this DSA, additional investigations were performed. These included a flow crossmatch with donor cells and recipient sera from three different samples (Table 1) , which demonstrated that the B-cell crossmatch was negative but high negative corresponding to the rising DSA levels. As the recipient was pancytopenic, we could not perform an autocrossmatch to rule out if the previous reactivity was due to an auto-antibody. Thus we performed surrogate crossmatches with two additional donors that were DRB1*04:04 using the same recipient sera and they were both negative. To rule out the possibility of rare donor null allele, surrogate crossmatch was performed with the donor cells and surrogate sera with high DRB1*04:04 MFI, which resulted in a positive crossmatch. These investigations led us to conclude that the recipient indeed demonstrated an antibody to 'self'. Finally we pre-treated the patient serum with fetal calf serum (FCS) prior to testing with the recipient serum as previously reported. 16 As the HLA antigens on the beads are derived from cell lines that have been cultured in FCS, one could speculate the FCS treatment provides target antigens that block the binding of naturally occurring heterophile antibodies to beads. Indeed testing recipient sera after FCS treatment resulted in removal of the 'spurious' anti-HLA reactivity (Figure 1) .
On the basis of these investigations and discussion with the principal investigator of the CTN 1101 study, the patient underwent a successful haploidentical transplant from her daughter with no transplant-related complications and at the time of writing this case report, it is 9 months since her transplantation having engrafted all three cell lines on day +23 post transplant.
HLA testing has undergone technical advances with a rapid, accurate and objective identification, and quantification of specific HLA antibodies. However it comes with its limitations as outlined by our case report. The current tests for anti-HLA antibody detection use Luminex-based assays, using polystyrene microbeads impregnated with a unique mixture of two fluorescent dyes that are simultaneously excited by a red laser at 635 nm. Although this is a sophisticated technique with high sensitivity, this assay can yield a potential underestimation of HLA antibody due to weak or even false-negative reactions due to interfering substances or prozone effects, 17, 18 immobilization procedure of the HLA molecules to the beads leading to altered tertiary structure of the molecules thereby exposing neoepitopes, which then lead to deviant reactions 19, 20 and the differences in relative density of a particular antigen between either pooled antigen phenotype beads and/ or, SAB and cell surfaces are all well-known limitations. 15, 21, 22 Our case further elucidates the dilemma when preexisting DSA's in high titer remain positive despite using several available tests to confirm their true positivity. The Luminex beads are prepared using peptides from human cell lines designed only to express single HLA alleles and these are cultured in the laboratory at which time they will get exposed to FCS thereby causing nonspecific protein expression on the beads giving false-positive and high antibody titers. This can be eliminated using the fetal bovine serum as a pretreatment before solid-phase HLA antibody testing as previously reported. 16 Our case demonstrates that failure to identify this limitation may lead to loss of potential donors when the donor pool for certain ethnicities is poor.
The main aim of this case report was to make the transplant team aware of self or auto HLA antibodies, and the artifacts that may be encountered when dealing with highly sensitive tests such as the Luminex or the SAB testing, and these artifacts can cause spurious reactions against self HLA antigens. If these tests are not interpreted cautiously and if further testing to confirm or negate the DSAs is not adequately performed, we may lose potential donors and as this case report outlines patients may be incorrectly deemed ineligible for clinical trials.
